可溶性CXCL16是与皮肌炎合并快速进展性间质性肺病相关的预后生物标志物
该研究在96例皮肌炎患者和55名健康对照中检测血清可溶性CXCL16水平,发现皮肌炎患者尤其合并快速进展性间质性肺病者sCXCL16显著升高,且高sCXCL16是快速进展性间质性肺病不良预后的独立因素,2年生存率显著降低。
要点
- 皮肌炎患者血清sCXCL16水平显著高于健康对照,合并快速进展性间质性肺病者更高。
- 多因素分析显示升高的sCXCL16是皮肌炎合并快速进展性间质性肺病不良预后的独立因素。
- 高sCXCL16水平患者的2年生存率显著低于低sCXCL16水平患者。
核心结论
- 较高的血清sCXCL16水平被确定为皮肌炎患者快速进展性间质性肺病的预测生物标志物,并与不良预后密切相关。
研究设计与样本
- 研究采用酶联免疫吸附试验检测96例皮肌炎患者和55名匹配健康供者的血清sCXCL16水平,并分析其与临床特征、实验室检查的相关性及对快速进展性间质性肺病的预测价值。
主要发现
- 皮肌炎患者(n=96)血清sCXCL16水平为3.264 ± 1.516 ng/mL,显著高于健康供者(n=55)的1.781 ± 0.318 ng/mL。
- 合并快速进展性间质性肺病的皮肌炎患者(n=31)血清sCXCL16水平为4.441 ± 1.706 ng/mL,高于全体皮肌炎患者水平。
- sCXCL16水平与血清铁蛋白、C反应蛋白、红细胞沉降率、乳酸脱氢酶、羟基丁酸脱氢酶水平呈正相关,与外周淋巴细胞百分比呈负相关,与抗黑色素瘤分化相关基因5抗体、Krebs von den Lungen-6或肌酸激酶水平无相关性。
- 多因素分析显示升高的sCXCL16是皮肌炎患者快速进展性间质性肺病不良预后的独立因素。
- 高sCXCL16水平患者的2年生存率显著低于低sCXCL16水平患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rapidly progressive interstitial lung disease (RPILD) in patients with dermatomyositis (DM) significantly impacts prognosis, leading to high mortality rates. Although several indicators have been demonstrated to strongly correlate with the risk of developing RPILD, their clinical utility still needs to be investigated. The objective of this study was to investigate the clinical significance of soluble CXCL16 (sCXCL16) in DM patients complicated with RPILD. METHODS: Serum sCXCL16 was measured by enzyme-linked immunosorbent assay in 96 patients with DM and 55 matching healthy donors. Correlations between sCXCL16 levels and clinical features, laboratory examinations and the predictive value of baseline sCXCL16 level for RPILD were analysed. RESULTS: The serum sCXCL16 levels were significantly higher in patients with DM (n = 96, 3.264 ± 1.516 ng/mL) compared with healthy donors (n = 55, 1.781 ± 0.318 ng/mL), especially in DM complicated with RPILD (n = 31, 4.441 ± 1.706 ng/mL). The sCXCL16 levels were positively correlated with levels of serum ferritin, C reactive protein, erythrocyte sedimentation rate, lactate dehydrogenase, hydroxybutyrate dehydrogenase, and negatively correlated with peripheral lymphocytes percentage, but showed no correlation with levels of anti-melanoma differentiation-associated gene 5 antibody, Krebs von den Lungen-6 or creatine kinase. Multivariable analysis showed that elevated sCXCL16 was an independent prognostic factor for poor prognosis of RPILD in patients with DM. The 2-year survival rate was significantly lower in patients with high sCXCL16 level than in those with low sCXCL16 level. CONCLUSION: A higher serum sCXCL16 level was identified as a predictive biomarker of RPILD in patients with DM, and closely associated with poor prognosis.
引用
- Li C, Han Y, Li X, et al. Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis. Semin Arthritis Rheum. 2024. PMID: 38843569. doi:10.1016/j.semarthrit.2024.152483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。